{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/LDX.AU"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LDX.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LDX.AU\",,,,,undefined,":{"symbol":"LDX.AU","market":"AU","secType":"STK","nameCN":"LUMOS DIAGNOSTICS HOLDINGS L","latestPrice":0.025,"timestamp":1744870320000,"preClose":0.022,"halted":0,"volume":10046021,"delay":0,"nameEN":"LUMOS DIAGNOSTICS HOLDINGS L","floatShares":359102273,"shares":748523022,"eps":-0.014262816499286233,"marketStatus":"Market Closed","change":0.003,"latestTime":"04-17 16:12:00 AEST","open":0.022,"high":0.027,"low":0.022,"amount":258909,"amplitude":0.227273,"askPrice":0.026,"askSize":657301,"bidPrice":0.025,"bidSize":79827,"shortable":3,"etf":0,"ttmEps":-0.014262816499286233,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1745280000000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":0.022,"openAndCloseTimeList":[[1744848000000,1744869600000]],"volumeRatio":19.33098870551296,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LDX.AU\",,,,,undefined,":{"symbol":"LDX.AU","floatShares":359102273,"roa":"-13.86%","roe":"-52.41%","lyrEps":-0.029034,"volumeRatio":19.33098870551296,"shares":748523022,"dividePrice":0,"high":0.027,"amplitude":0.227273,"preClose":0.022,"low":0.022,"week52Low":0.019,"pbRate":"1.22","psRate":"0.81","week52High":0.063,"institutionHeld":0,"latestPrice":0.025,"committee":-0.783411,"eps":-0.014262816499286233,"divideRate":0,"volume":10046021,"delay":0,"ttmEps":-0.014262816499286233,"open":0.022,"prevYearClose":0.035,"prevWeekClose":0.022,"prevMonthClose":0.024,"prevQuarterClose":0.024,"fiveDayClose":0.021,"twentyDayClose":0.023,"sixtyDayClose":0.043},"@#url:\"https://hq.skytigris.cn/market/plate/belongs/LDX.AU\",params:#limit:6,delay:false,,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LDX.AU\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2528753498","title":"Lumos Diagnostics to Receive Medicare Reimbursement for Test in Two US Regions; Shares Rise 14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2528753498","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528753498?lang=en_us&edition=fundamental","pubTime":"2025-04-17 13:38","pubTimestamp":1744868321,"startTime":"0","endTime":"0","summary":"Lumos Diagnostics Holdings  said it will start receiving Medicare reimbursement for its FebriDx rapid diagnostic test designed to distinguish bacterial from viral respiratory infections in two US regions, according to a Thursday filing with the Australian bourse.Effective this month, the test has been included in the Medicare fee schedule in the Palmetto and Novitas regions at a rate of $41.38 per test, the filing said.The test is reimbursable in both moderately complex and clinical laboratory improvement amendments waived settings, the company said.Shares of the company rose about 14% in recent Thursday trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","RF","BK4211","BK7126","LDX.AU","BK4588"],"gpt_icon":0},{"id":"2517499140","title":"Lacklustre Performance Is Driving Lumos Diagnostics Holdings Limited's (ASX:LDX) 29% Price Drop","url":"https://stock-news.laohu8.com/highlight/detail?id=2517499140","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517499140?lang=en_us&edition=fundamental","pubTime":"2025-03-08 04:54","pubTimestamp":1741380884,"startTime":"0","endTime":"0","summary":"To the annoyance of some shareholders, Lumos Diagnostics Holdings Limited ( ASX:LDX ) shares are down a considerable...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6022000-choice2-main-header/1585186808155","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6022000-choice2-main-header/1585186808155"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-ldx/lumos-diagnostics-holdings-shares/news/lacklustre-performance-is-driving-lumos-diagnostics-holdings","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7126","LDX.AU"],"gpt_icon":0},{"id":"2516701935","title":"Lumos Diagnostics Holdings Agrees to Expand Scope of Work for Women's Health Test","url":"https://stock-news.laohu8.com/highlight/detail?id=2516701935","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516701935?lang=en_us&edition=fundamental","pubTime":"2025-03-03 14:40","pubTimestamp":1740984034,"startTime":"0","endTime":"0","summary":"Lumos Diagnostics Holdings  and Hologic agreed to expand the scope of work for the new fetal fibronectin test, according to a Monday Australian bourse filing.The expanded scope of work relates to phase 3 of the development agreement, which focuses on delivery of the system prototype and will include the incorporation of additional hardware features into the proprietary reader technology.This is expected to generate additional fee revenue for Lumos of between $600,000 to $800,000.Phase 2 of the development agreement is expected to complete around April. The phase seeks to demonstrate that the assay can detect a biomarker.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7126","LDX.AU"],"gpt_icon":0},{"id":"2514381566","title":"BRIEF-Lumos Diagnostics Posts HY Loss Attributable $2.8 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2514381566","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514381566?lang=en_us&edition=fundamental","pubTime":"2025-02-27 09:29","pubTimestamp":1740619740,"startTime":"0","endTime":"0","summary":"BRIEF-Lumos Diagnostics Posts HY Loss Attributable $2.8 MlnFeb 27 (Reuters) - Lumos Diagnostics Holdings Ltd LDX.AX:HY LOSS ATTRIBUTABLE $2.8 MILLIONHY REVENUES FROM ORDINARY ACTIVITIES $6.3 MILLIONFurther company coverage: LDX.AX ((Reuters.Briefs@thomsonreuters.com;;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nFWN3PH1SL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LDX.AU","BK7126"],"gpt_icon":0}],"pageSize":4,"totalPage":5,"pageCount":1,"totalSize":17,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LDX.AU\",params:#limit:5,,,undefined,":[{"date":"2024-07-31","symbol":"LDX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1722384000000,"name":null,"time":"","dateTimestamp":1722348000000,"actualEps":null},{"date":"2024-02-28","symbol":"LDX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1709074800000,"name":null,"time":"","dateTimestamp":1709038800000,"actualEps":null},{"market":"AU","date":"2023-08-30","symbol":"LDX.AU","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1693317600000,"reportTimeType":"","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LDX.AU\",market:\"AU\",,,undefined,":[]}}